The noninvasive assessment of tumor hypoxia in vivo is under active investigationbecause
hypoxia has been shown to be an importantprognosticfactorfortherapyresistance …

Tumor hypoxia is an important prognostic indicator for cancer therapy outcome. EF5 {2-(2-
nitro-1 [H]-imidazol-1-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl)-acetamide} has been employed …

18F-labeled fluoroerythronitroimidazole (FETNIM) has been suggested as a marker of tumor
hypoxia for use with PET. Our goal was to evaluate the pharmacokinetic properties of [18F] …

Abstract Development of hypoxia-targeted therapies has stimulated the search for clinically
applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of [18 F] …

Clinical studies using Eppendorf needle sensors have invariably documented the resistance
of hypoxic human tumors to therapy. These studies first documented the need for individual …

The study was performed to compare the 18F-labeled nitroimidazole compound
fluoroazomycin arabinoside (18F-FAZA) with the standard hypoxia tracer fluoromisonidazole …

PURPOSE: To develop a hydrophilic ligand to image tumor hypoxia at positron emission
tomography (PET). MATERIALS AND METHODS: Biodistribution of fluorine-18-labeled …

Background To facilitate hypoxia imaging in a clinical setting, we developed 1-(2, 2-
dihydroxymethyl-3-[18 F]-fluoropropyl)-2-nitroimidazole ([18 F] DiFA) as a new tracer that …

Purpose The primary purpose of this study was to assess the biodistribution and radiation
dose resulting from administration of 18 F-EF5, a lipophilic 2-nitroimidazole hypoxia marker …

For many years, it has been known that hypoxia affects the response to radiotherapy in
human cancers. Hypoxic regions can develop as a tumor grows beyond the ability of its …